W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

27 June, 2022

Summary of information indicated by applicants to be kept confidential in selected areas of the documentation published by AOTMiT (applicant’s analyses, verification analyses, positions of the Transparency Council, recommendations of the President) in the evaluation of reimbursement applications for the year 2021 and Q1 2022.

23 May, 2023

Opinion of the Transparency Council – dexamethasone

23 May, 2023

Opinion of the Transparency Council – amendments to part B of the drug programme B.70

23 May, 2023

Opinion of the Transparency Council – health policy programme of the City of Białystok

23 May, 2023

Opinion of the Transparency Council – health policy programme of the City of Zduńska Wola

23 May, 2023

Position of the Transparency Council – Adtralza (tralokinumab)

22 May, 2023

Meeting of the Transparency Council 20/2023 on 22 May 2023 – Update

16 May, 2023

The Transparency Council meeting 20/2023 on 22 May 2023

16 May, 2023

Opinion of the Transparency Council – desmopressin

16 May, 2023

Opinion of the Transparency Council – fentanyl

16 May, 2023

Opinion of the Transparency Council – paclitaxel

16 May, 2023

Opinion of the Transparency Council – carboplatin

16 May, 2023

Position of the Transparency Council – Forxiga (dapagliflozin)

16 May, 2023

Position of the Transparency Council – Forxiga (dapagliflozin)

16 May, 2023

Opinion of the Transparency Council – e-stethoscopes

16 May, 2023

Opinion of the Transparency Council – health policy programme of the Municipality of Kamieniec Ząbkowicki

16 May, 2023

Opinion of the Transparency Council – health policy programme of the Municipality of Piaseczno

11 May, 2023

The Transparency Council meeting 19/2023 on 15 May 2023

10 May, 2023

Opinion of the Transparency Council – lisinopril + amlodipine

10 May, 2023

Opinion of the Transparency Council – candesartan + amlodipine

10 May, 2023

Opinion of the Transparency Council – candesartan + hydrochlorothiazide

10 May, 2023

Opinion of the Transparency Council – amlodipine + valsartan+ hydrochlorothiazide

10 May, 2023

Opinion of the Transparency Council – amlodipine + valsartan

10 May, 2023

Opinion of the Transparency Council – telmisartan + hydrochlorothiazide

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy